Jump to content
TedderVision
Kurt Faulhammer

Naloxone Accessibility Act

Recommended Posts

Mr. Faulhammer, For himself with thanks to Ms. Edwards, introduces

A BILL

To prevent deaths occurring from drug overdoses.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Naloxone Accessibility Act”.

SEC. 2. OVERDOSE PREVENTION PROGRAMS.

Title III of the Public Health Service Act (42 U.S.C. 241 et seq.) is amended by adding at the end the following:

“PART W—OVERDOSE PREVENTION PROGRAMS
“SEC. 399OO. COOPERATIVE AGREEMENT PROGRAM TO REDUCE DRUG OVERDOSE DEATHS.

“(a) Program Authorized.—The Secretary, acting through the Administrator of the Substance Abuse and Mental Health Services Administration, shall enter into cooperative agreements with eligible entities to enable the eligible entities to reduce deaths occurring from overdoses of drugs.

“(b) Eligible Entities.—To be eligible to receive a cooperative agreement under this section, an entity shall be a State, local, or tribal government, a correctional institution, a law enforcement agency, a community agency, a professional organization in the field of poison control and surveillance, or a private nonprofit organization.

“(c) Application.—

“(1) IN GENERAL.—An eligible entity desiring a cooperative agreement under this section shall submit to the Secretary an application at such time, in such manner, and containing such information as the Secretary may require.

“(2) CONTENTS.—An application under paragraph (1) shall include—

“(A) a description of the activities to be funded through the cooperative agreement; and

“(B) evidence that the eligible entity has the capacity to carry out such activities.

“(d) Priority.—In entering into cooperative agreements under subsection (a), the Secretary shall give priority to eligible entities that—

“(1) are a public health agency or community-based organization; and

“(2) have expertise in preventing deaths occurring from overdoses of drugs in populations at high risk of such deaths.

“(e) Eligible Activities.—As a condition of receipt of a cooperative agreement under this section, an eligible entity shall agree to use the cooperative agreement to do each of the following:

“(1) Purchase and distribute the drug naloxone or a similarly effective medication.

“(2) Carry out one or more of the following activities:

“(A) Educating prescribers and pharmacists about overdose prevention and naloxone prescription, or prescriptions of a similarly effective medication.

“(B) Training first responders, other individuals in a position to respond to an overdose, and law enforcement and corrections officials on the effective response to individuals who have overdosed on drugs. Training pursuant to this subparagraph may include any activity that is educational, instructional, or consultative in nature, and may include volunteer training, awareness building exercises, outreach to individuals who are at-risk of a drug overdose, and distribution of educational materials.

“(C) Implementing and enhancing programs to provide overdose prevention, recognition, treatment, and response to individuals in need of such services.

“(D) Educating the public and providing outreach to the public about overdose prevention and naloxone prescriptions, or prescriptions of other similarly effective medications.

“(f) Coordinating Center.—

“(1) ESTABLISHMENT.—The Secretary shall establish and provide for the operation of a coordinating center responsible for—

“(A) collecting, compiling, and disseminating data on the programs and activities under this section, including tracking and evaluating the distribution and use of naloxone and other similarly effective medication;

“(B) evaluating such data and, based on such evaluation, developing best practices for preventing deaths occurring from drug overdoses;

“(C) making such best practices specific to the type of community involved;

“(D) coordinating and harmonizing data collection measures;

“(E) evaluating the effects of the program on overdose rates; and

“(F) education and outreach to the public about overdose prevention and prescription of naloxone and other similarly effective medication.

“(2) REPORTS TO CENTER.—As a condition on receipt of a cooperative agreement under this section, an eligible entity shall agree to prepare and submit, not later than 90 days after the end of the cooperative agreement period, a report to such coordinating center and the Secretary describing the results of the activities supported through the cooperative agreement.

“(g) Duration.—The period of a cooperative agreement under this section shall be 4 years.

“(h) Definition.—In this part, the term ‘drug’ —

“(1) means a drug, as defined in section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321); and

“(2) includes controlled substances, as defined in section 102 of the Controlled Substances Act (21 U.S.C. 802).

“(i) Authorization Of Appropriations.—There are authorized to be appropriated $20,000,000 to carry out this section for each of the fiscal years 2016 through 2020.

“SEC. 399OO–1. SURVEILLANCE CAPACITY BUILDING.

“(a) Program Authorized.—The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall award cooperative agreements to eligible entities to improve fatal and nonfatal drug overdose surveillance and reporting capabilities, including—

“(1) providing training to improve identification of drug overdose as the cause of death by coroners and medical examiners;

“(2) establishing, in cooperation with the National Poison Data System, coroners, and medical examiners, a comprehensive national program for surveillance of, and reporting to an electronic database on, drug overdose deaths in the United States; and

“(3) establishing, in cooperation with the National Poison Data System, a comprehensive national program for surveillance of, and reporting to an electronic database on, fatal and nonfatal drug overdose occurrences, including epidemiological and toxicologic analysis and trends.

“(b) Eligible Entity.—To be eligible to receive a cooperative agreement under this section, an entity shall be—

“(1) a State, local, or tribal government; or

“(2) the National Poison Data System working in conjunction with a State, local, or tribal government.

“(c) Application.—

“(1) IN GENERAL.—An eligible entity desiring a cooperative agreement under this section shall submit to the Secretary an application at such time, in such manner, and containing such information as the Secretary may require.

“(2) CONTENTS.—The application described in paragraph (1) shall include—

“(A) a description of the activities to be funded through the cooperative agreement; and

“(B) evidence that the eligible entity has the capacity to carry out such activities.

“(d) Report.—As a condition of receipt of a cooperative agreement under this section, an eligible entity shall agree to prepare and submit, not later than 90 days after the end of the cooperative agreement period, a report to the Secretary describing the results of the activities supported through the cooperative agreement.

“(e) National Poison Data System.—In this section, the term ‘National Poison Data System’ means the system operated by the American Association of Poison Control Centers, in partnership with the Centers for Disease Control and Prevention, for real-time local, State, and national electronic reporting, and the corresponding database network.

“(f) Authorization Of Appropriations.—There are authorized to be appropriated to carry out this section $5,000,000 for each of the fiscal years 2016 through 2020.

“SEC. 399OO–2. REDUCING OVERDOSE DEATHS.

“(a) Prevention Of Drug Overdose.—Not later than 180 days after the date of the enactment of this section, the Secretary, in consultation with a task force comprised of stakeholders, shall develop a plan to reduce the number of deaths occurring from overdoses of drugs and shall submit the plan to Congress. The plan shall include—

“(1) a plan for implementation of a public health campaign to educate prescribers and the public about overdose prevention and prescription of naloxone and other similarly effective medication;

“(2) recommendations for improving and expanding overdose prevention programming; and

“(3) recommendations for such legislative or administrative action as the Secretary determines appropriate.

“(b) Task Force Representation.—

“(1) REQUIRED MEMBERS.—The task force under subsection (a) shall include at least one representative of each of the following:

“(A) Individuals directly impacted by drug overdose.

“(B) Direct service providers who engage individuals at risk of a drug overdose.

“(C) Drug overdose prevention advocates.

“(D) The National Institute on Drug Abuse.

“(E) The Center for Substance Abuse Treatment.

“(F) The Centers for Disease Control and Prevention.

“(G) The Health Resources and Services Administration.

“(H) The Food and Drug Administration.

“(I) The Office of National Drug Control Policy.

“(J) The American Medical Association.

“(K) The American Association of Poison Control Centers.

“(L) The Federal Bureau of Prisons.

“(M) The Centers for Medicare & Medicaid Services.

“(N) The Department of Justice.

“(O) The Department of Defense.

“(P) The Department of Veterans Affairs.

“(Q) First responders.

“(R) Law enforcement.

“(S) State agencies responsible for drug overdose prevention.

“(2) ADDITIONAL MEMBERS.—In addition to the representatives required by paragraph (1), the task force under subsection (a) may include other individuals with expertise relating to drug overdoses or representatives of entities with expertise relating to drug overdoses, as the Secretary determines appropriate.”.

SEC. 3. OVERDOSE PREVENTION RESEARCH.

Subpart 15 of part C of title IV of the Public Health Service Act (42 U.S.C. 285o et seq.) is amended by adding at the end the following:

“SEC. 464Q. OVERDOSE PREVENTION RESEARCH.

“(a) Overdose Research.—The Director of the Institute shall prioritize and conduct or support research on drug overdose and overdose prevention. The primary aims of this research shall include—

“(1) an examination of circumstances that contribute to drug overdose and identification of drugs associated with fatal overdose;

“(2) an evaluation of existing overdose prevention methods;

“(3) pilot programs or research trials on new overdose prevention strategies or programs that have not been studied in the United States;

“(4) scientific research concerning the effectiveness of overdose prevention programs, including how to effectively implement and sustain such programs;

“(5) comparative effectiveness research of model programs; and

“(6) implementation of science research concerning effective overdose prevention programming examining how to implement and sustain overdose prevention programming.

“(b) Formulations Of Naloxone.—The Director of the Institute shall support research on the development of formulations of naloxone, and other similarly effective medications, and dosage delivery devices specifically intended to be used by lay persons or first responders for the prehospital treatment of unintentional drug overdose.

“(c) Definition.—In this section, the term ‘drug’ has the meaning given such term in section 399OO.

“(d) Authorization Of Appropriations.—There are authorized to be appropriated to carry out this section $5,000,000 for each of the fiscal years 2016 through 2020.”.

PES: 

This bill amends the Public Health Service Act to require the Substance Abuse and Mental Health Services Administration (SAMHSA) to enter into cooperative agreements to reduce deaths from drug overdoses by: (1) purchasing and distributing naloxone (a medication that rapidly reverses overdose from heroin or other drugs with effects similar to opium) or a similar drug; and (2) educating or training the public, first responders, or health professionals on drug overdose prevention or response.

SAMHSA must establish a coordinating center and develop a plan to reduce drug overdose deaths by educating the public about overdose prevention and recommending improvements to overdose prevention programs.

The Centers for Disease Control and Prevention must improve drug overdose surveillance by entering into cooperative agreements to: (1) provide training to improve identification of drug overdose as the cause of death, and (2) establish a national program for reporting drug overdoses.

The National Institute on Drug Abuse (NIDA) must prioritize, conduct, and support research on circumstances that contribute to drug overdose, drugs associated with fatal overdose, and overdose prevention methods. NIDA must support research on drug overdose treatments that can be administered by lay persons or first responders.

 

 

Share this post


Link to post
Share on other sites
PLAYER NAME
Republicans Democrats
NAT EV BUS MR ML SJW  PRO GLO
Change 1 1 1 1 1 1 1 1

Share this post


Link to post
Share on other sites

I move to add an amendment section 2, that adds the following under Section 2 Overdose prevention programs with:

 

PRESCRIPTION DRUG, HEROIN, AND OTHER CONTROLLED SUBSTANCE ABUSE

              PREVENTION.

    Part P of title III of the Public Health Service Act (42 U.S.C.

280g) is amended by adding at the end the following:

 

``SEC. 399V-7. PRESCRIPTION DRUG, HEROIN, AND OTHER CONTROLLED

              SUBSTANCE ABUSE PREVENTION.

    ``(a) Training Grants.--

            ``(1) In general.--The Secretary shall award 5-year grants

        to eligible entities to facilitate training in order to

        increase the capacity of health care providers to conduct

        patient screening, brief interventions, and referral to

        treatment as needed, such as in health care settings to prevent

        the abuse of prescription drugs, heroin, and other controlled

        substances. The grant program under this section may be

        coordinated with the Screening Brief Intervention and Referral

        to Treatment grant program of the Substance Abuse and Mental

        Health Services Administration, or other appropriate programs.

            ``(2) Eligible entities.--In this subsection, the term

        `eligible entity' includes--

                    ``(A) States;

                    ``(B) physician organizations;

                    ``(C) continuing education entities, such as health

                profession boards or health accrediting bodies;

                    ``(D) peer recovery organizations; and

                    ``(E) other appropriate health or professional

                education organizations or institutions.

    ``(b) Expansion of Prescribing Authority.--The Secretary, acting

through the Administrator of the Health Resources and Services

Administration, shall award grants to States for the purpose of

evaluating the prospect of the health professions board of such States

reviewing and expanding prescribing authorities of providers, such as

advance practice nurses and physician's assistants, with respect to

prescribing drugs for the treatment of the abuse of prescription drugs,

heroin, or other controlled substances.''.

Share this post


Link to post
Share on other sites

In addition, I would like to propose an amendment to add the following section:

SEC. #?. GAO REPORT.

    The Comptroller General of the United States shall--

            (1) review opioid abuse programs, heroin abuse programs,

        and policies in Federal agencies and best practices with

        respect to opioid and heroin abuse and overdose programs of the

        States; and

            (2) not later than 18 months after the date of enactment of

        this Act, issue a report to Congress on its findings and

        recommendations on ways to reduce opioid and heroin abuse and

        overdoses.

Share this post


Link to post
Share on other sites
37 minutes ago, Doomhammer said:

In addition, I would like to propose an amendment to add the following section:

SEC. #?. GAO REPORT.

    The Comptroller General of the United States shall--

            (1) review opioid abuse programs, heroin abuse programs,

        and policies in Federal agencies and best practices with

        respect to opioid and heroin abuse and overdose programs of the

        States; and

            (2) not later than 18 months after the date of enactment of

        this Act, issue a report to Congress on its findings and

        recommendations on ways to reduce opioid and heroin abuse and

        overdoses.

Mr Speaker,

I second the amendment and yield.

Share this post


Link to post
Share on other sites
On 7/7/2018 at 7:00 PM, Kurt Faulhammer said:

Mr. Faulhammer, For himself with thanks to Ms. Edwards, introduces

A BILL

To prevent deaths occurring from drug overdoses.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Naloxone Accessibility Act”.

SEC. 2. OVERDOSE PREVENTION PROGRAMS.

Title III of the Public Health Service Act (42 U.S.C. 241 et seq.) is amended by adding at the end the following:

“PART W—OVERDOSE PREVENTION PROGRAMS
“SEC. 399OO. COOPERATIVE AGREEMENT PROGRAM TO REDUCE DRUG OVERDOSE DEATHS.

“(a) Program Authorized.—The Secretary, acting through the Administrator of the Substance Abuse and Mental Health Services Administration, shall enter into cooperative agreements with eligible entities to enable the eligible entities to reduce deaths occurring from overdoses of drugs.

“(b) Eligible Entities.—To be eligible to receive a cooperative agreement under this section, an entity shall be a State, local, or tribal government, a correctional institution, a law enforcement agency, a community agency, a professional organization in the field of poison control and surveillance, or a private nonprofit organization.

“(c) Application.—

“(1) IN GENERAL.—An eligible entity desiring a cooperative agreement under this section shall submit to the Secretary an application at such time, in such manner, and containing such information as the Secretary may require.

“(2) CONTENTS.—An application under paragraph (1) shall include—

“(A) a description of the activities to be funded through the cooperative agreement; and

“(B) evidence that the eligible entity has the capacity to carry out such activities.

“(d) Priority.—In entering into cooperative agreements under subsection (a), the Secretary shall give priority to eligible entities that—

“(1) are a public health agency or community-based organization; and

“(2) have expertise in preventing deaths occurring from overdoses of drugs in populations at high risk of such deaths.

“(e) Eligible Activities.—As a condition of receipt of a cooperative agreement under this section, an eligible entity shall agree to use the cooperative agreement to do each of the following:

“(1) Purchase and distribute the drug naloxone or a similarly effective medication.

“(2) Carry out one or more of the following activities:

“(A) Educating prescribers and pharmacists about overdose prevention and naloxone prescription, or prescriptions of a similarly effective medication.

“(B) Training first responders, other individuals in a position to respond to an overdose, and law enforcement and corrections officials on the effective response to individuals who have overdosed on drugs. Training pursuant to this subparagraph may include any activity that is educational, instructional, or consultative in nature, and may include volunteer training, awareness building exercises, outreach to individuals who are at-risk of a drug overdose, and distribution of educational materials.

“(C) Implementing and enhancing programs to provide overdose prevention, recognition, treatment, and response to individuals in need of such services.

“(D) Educating the public and providing outreach to the public about overdose prevention and naloxone prescriptions, or prescriptions of other similarly effective medications.

“(f) Coordinating Center.—

“(1) ESTABLISHMENT.—The Secretary shall establish and provide for the operation of a coordinating center responsible for—

“(A) collecting, compiling, and disseminating data on the programs and activities under this section, including tracking and evaluating the distribution and use of naloxone and other similarly effective medication;

“(B) evaluating such data and, based on such evaluation, developing best practices for preventing deaths occurring from drug overdoses;

“(C) making such best practices specific to the type of community involved;

“(D) coordinating and harmonizing data collection measures;

“(E) evaluating the effects of the program on overdose rates; and

“(F) education and outreach to the public about overdose prevention and prescription of naloxone and other similarly effective medication.

“(2) REPORTS TO CENTER.—As a condition on receipt of a cooperative agreement under this section, an eligible entity shall agree to prepare and submit, not later than 90 days after the end of the cooperative agreement period, a report to such coordinating center and the Secretary describing the results of the activities supported through the cooperative agreement.

“(g) Duration.—The period of a cooperative agreement under this section shall be 4 years.

“(h) Definition.—In this part, the term ‘drug’ —

“(1) means a drug, as defined in section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321); and

“(2) includes controlled substances, as defined in section 102 of the Controlled Substances Act (21 U.S.C. 802).

“(i) Authorization Of Appropriations.—There are authorized to be appropriated $20,000,000 to carry out this section for each of the fiscal years 2016 through 2020.

“SEC. 399OO–1. SURVEILLANCE CAPACITY BUILDING.

“(a) Program Authorized.—The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall award cooperative agreements to eligible entities to improve fatal and nonfatal drug overdose surveillance and reporting capabilities, including—

“(1) providing training to improve identification of drug overdose as the cause of death by coroners and medical examiners;

“(2) establishing, in cooperation with the National Poison Data System, coroners, and medical examiners, a comprehensive national program for surveillance of, and reporting to an electronic database on, drug overdose deaths in the United States; and

“(3) establishing, in cooperation with the National Poison Data System, a comprehensive national program for surveillance of, and reporting to an electronic database on, fatal and nonfatal drug overdose occurrences, including epidemiological and toxicologic analysis and trends.

“(b) Eligible Entity.—To be eligible to receive a cooperative agreement under this section, an entity shall be—

“(1) a State, local, or tribal government; or

“(2) the National Poison Data System working in conjunction with a State, local, or tribal government.

“(c) Application.—

“(1) IN GENERAL.—An eligible entity desiring a cooperative agreement under this section shall submit to the Secretary an application at such time, in such manner, and containing such information as the Secretary may require.

“(2) CONTENTS.—The application described in paragraph (1) shall include—

“(A) a description of the activities to be funded through the cooperative agreement; and

“(B) evidence that the eligible entity has the capacity to carry out such activities.

“(d) Report.—As a condition of receipt of a cooperative agreement under this section, an eligible entity shall agree to prepare and submit, not later than 90 days after the end of the cooperative agreement period, a report to the Secretary describing the results of the activities supported through the cooperative agreement.

“(e) National Poison Data System.—In this section, the term ‘National Poison Data System’ means the system operated by the American Association of Poison Control Centers, in partnership with the Centers for Disease Control and Prevention, for real-time local, State, and national electronic reporting, and the corresponding database network.

“(f) Authorization Of Appropriations.—There are authorized to be appropriated to carry out this section $5,000,000 for each of the fiscal years 2016 through 2020.

“SEC. 399OO–2. REDUCING OVERDOSE DEATHS.

“(a) Prevention Of Drug Overdose.—Not later than 180 days after the date of the enactment of this section, the Secretary, in consultation with a task force comprised of stakeholders, shall develop a plan to reduce the number of deaths occurring from overdoses of drugs and shall submit the plan to Congress. The plan shall include—

“(1) a plan for implementation of a public health campaign to educate prescribers and the public about overdose prevention and prescription of naloxone and other similarly effective medication;

“(2) recommendations for improving and expanding overdose prevention programming; and

“(3) recommendations for such legislative or administrative action as the Secretary determines appropriate.

“(b) Task Force Representation.—

“(1) REQUIRED MEMBERS.—The task force under subsection (a) shall include at least one representative of each of the following:

“(A) Individuals directly impacted by drug overdose.

“(B) Direct service providers who engage individuals at risk of a drug overdose.

“(C) Drug overdose prevention advocates.

“(D) The National Institute on Drug Abuse.

“(E) The Center for Substance Abuse Treatment.

“(F) The Centers for Disease Control and Prevention.

“(G) The Health Resources and Services Administration.

“(H) The Food and Drug Administration.

“(I) The Office of National Drug Control Policy.

“(J) The American Medical Association.

“(K) The American Association of Poison Control Centers.

“(L) The Federal Bureau of Prisons.

“(M) The Centers for Medicare & Medicaid Services.

“(N) The Department of Justice.

“(O) The Department of Defense.

“(P) The Department of Veterans Affairs.

“(Q) First responders.

“(R) Law enforcement.

“(S) State agencies responsible for drug overdose prevention.

“(2) ADDITIONAL MEMBERS.—In addition to the representatives required by paragraph (1), the task force under subsection (a) may include other individuals with expertise relating to drug overdoses or representatives of entities with expertise relating to drug overdoses, as the Secretary determines appropriate.”.

SEC. 3. OVERDOSE PREVENTION RESEARCH.

Subpart 15 of part C of title IV of the Public Health Service Act (42 U.S.C. 285o et seq.) is amended by adding at the end the following:

“SEC. 464Q. OVERDOSE PREVENTION RESEARCH.

“(a) Overdose Research.—The Director of the Institute shall prioritize and conduct or support research on drug overdose and overdose prevention. The primary aims of this research shall include—

“(1) an examination of circumstances that contribute to drug overdose and identification of drugs associated with fatal overdose;

“(2) an evaluation of existing overdose prevention methods;

“(3) pilot programs or research trials on new overdose prevention strategies or programs that have not been studied in the United States;

“(4) scientific research concerning the effectiveness of overdose prevention programs, including how to effectively implement and sustain such programs;

“(5) comparative effectiveness research of model programs; and

“(6) implementation of science research concerning effective overdose prevention programming examining how to implement and sustain overdose prevention programming.

“(b) Formulations Of Naloxone.—The Director of the Institute shall support research on the development of formulations of naloxone, and other similarly effective medications, and dosage delivery devices specifically intended to be used by lay persons or first responders for the prehospital treatment of unintentional drug overdose.

“(c) Definition.—In this section, the term ‘drug’ has the meaning given such term in section 399OO.

“(d) Authorization Of Appropriations.—There are authorized to be appropriated to carry out this section $5,000,000 for each of the fiscal years 2016 through 2020.”.

PES: 

This bill amends the Public Health Service Act to require the Substance Abuse and Mental Health Services Administration (SAMHSA) to enter into cooperative agreements to reduce deaths from drug overdoses by: (1) purchasing and distributing naloxone (a medication that rapidly reverses overdose from heroin or other drugs with effects similar to opium) or a similar drug; and (2) educating or training the public, first responders, or health professionals on drug overdose prevention or response.

SAMHSA must establish a coordinating center and develop a plan to reduce drug overdose deaths by educating the public about overdose prevention and recommending improvements to overdose prevention programs.

 The Centers for Disease Control and Prevention must improve drug overdose surveillance by entering into cooperative agreements to: (1) provide training to improve identification of drug overdose as the cause of death, and (2) establish a national program for reporting drug overdoses.

The National Institute on Drug Abuse (NIDA) must prioritize, conduct, and support research on circumstances that contribute to drug overdose, drugs associated with fatal overdose, and overdose prevention methods. NIDA must support research on drug overdose treatments that can be administered by lay persons or first responders.

  

 

Faulhammer
Republicans Democrats
NAT EV BUS MR MD SJW PRO GL
Previous Rating 14 6 21 20 17 14 13 10
Change 1 1 2 2 2 1 1 1
New Rating 15 7 23 22 19 15 14 11

Share this post


Link to post
Share on other sites

Mr. Speaker,

Naloxone is a life saving medicine used to treat drug overdoses. This bill provides local first responders with the training and access they need to administer naloxone to patients.

I yield. 

Share this post


Link to post
Share on other sites

  • Recently Browsing   0 members

    No registered users viewing this page.

×